Bortezomib in combination with dexamethasone for relapsed multiple myeloma
Fifteen patients with advanced multiple myeloma were scheduled to receive bortezomib 1.3 mg/m 2 IV days 1, 4, 8, and 11 every 3 weeks for eight cycles in combination with dexamethasone. One patient (7%) achieved a complete response, 10 (67%) a partial response, and one (7%) a minor response (MR) res...
Gespeichert in:
| Veröffentlicht in: | Leukemia research 2005-05, Vol.29 (5), p.587-590 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 590 |
|---|---|
| container_issue | 5 |
| container_start_page | 587 |
| container_title | Leukemia research |
| container_volume | 29 |
| creator | Kropff, Martin H. Bisping, Guido Wenning, Doris Volpert, Sarah Tchinda, Joëlle Berdel, Wolfgang E. Kienast, Joachim |
| description | Fifteen patients with advanced multiple myeloma were scheduled to receive bortezomib 1.3
mg/m
2 IV days 1, 4, 8, and 11 every 3 weeks for eight cycles in combination with dexamethasone. One patient (7%) achieved a complete response, 10 (67%) a partial response, and one (7%) a minor response (MR) resulting in an overall response rate (≥MR) of 80% (9/9 with ≥ 2nd untreated and 3/6 with refractory relapse). Responses occurred after a median of 3 weeks and were independent of conventional prognostic parameters including deletion of chromosome 13. Adverse events, mainly myelosuppression, neuropathy and fatigue, were manageable. |
| doi_str_mv | 10.1016/j.leukres.2004.11.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67501838</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S014521260400387X</els_id><sourcerecordid>67501838</sourcerecordid><originalsourceid>FETCH-LOGICAL-c394t-abf97b01187719b0a709334cbe0bad5724bf09c2422951891476cb275fa23b423</originalsourceid><addsrcrecordid>eNqFkEtP3DAUhS0EginlJxRlxS6prx_jeFUV1KeQ2MDasp0b4WkcD3ZSSn89Gc1ILFmdzXfuufoI-QS0AQrrz5tmwPlPxtIwSkUD0CxxRFbQKl7LlstjsqIgZM2Arc_Ih1I2lFKpQZ-SM5BKSglsRX5fpzzh_xSDq8JY-RRdGO0U0lg9h-mx6vCfjTg92pJGrPqUq4yD3RbsqjgPU9gOWMUXHFK0H8lJb4eCF4c8Jw_fv93f_Kxv7378uvl6W3uuxVRb12vlKCyPKtCOWkU158I7pM52UjHheqo9E4xpCa0GodbeMSV7y7gTjJ-Tq_3dbU5PM5bJxFA8DoMdMc3FrJWk0PL2XRC0YC0HvYByD_qcSsnYm20O0eYXA9TsbJuNOdg2O9sGwCyx9C4PA7OL2L21DnoX4MsewMXH34DZFB9w9NiFjH4yXQrvTLwCxp6TUg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19428319</pqid></control><display><type>article</type><title>Bortezomib in combination with dexamethasone for relapsed multiple myeloma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Kropff, Martin H. ; Bisping, Guido ; Wenning, Doris ; Volpert, Sarah ; Tchinda, Joëlle ; Berdel, Wolfgang E. ; Kienast, Joachim</creator><creatorcontrib>Kropff, Martin H. ; Bisping, Guido ; Wenning, Doris ; Volpert, Sarah ; Tchinda, Joëlle ; Berdel, Wolfgang E. ; Kienast, Joachim</creatorcontrib><description>Fifteen patients with advanced multiple myeloma were scheduled to receive bortezomib 1.3
mg/m
2 IV days 1, 4, 8, and 11 every 3 weeks for eight cycles in combination with dexamethasone. One patient (7%) achieved a complete response, 10 (67%) a partial response, and one (7%) a minor response (MR) resulting in an overall response rate (≥MR) of 80% (9/9 with ≥ 2nd untreated and 3/6 with refractory relapse). Responses occurred after a median of 3 weeks and were independent of conventional prognostic parameters including deletion of chromosome 13. Adverse events, mainly myelosuppression, neuropathy and fatigue, were manageable.</description><identifier>ISSN: 0145-2126</identifier><identifier>EISSN: 1873-5835</identifier><identifier>DOI: 10.1016/j.leukres.2004.11.004</identifier><identifier>PMID: 15755512</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Boronic Acids - administration & dosage ; Bortezomib ; Chromosomes, Human, Pair 13 - genetics ; Dexamethasone ; Dexamethasone - administration & dosage ; Female ; Humans ; Male ; Middle Aged ; Multiple myeloma ; Multiple Myeloma - drug therapy ; Neoplasm Recurrence, Local - drug therapy ; Prognosis ; Pyrazines - administration & dosage ; Remission Induction ; Salvage Therapy ; Sequence Deletion ; Treatment Outcome</subject><ispartof>Leukemia research, 2005-05, Vol.29 (5), p.587-590</ispartof><rights>2004 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c394t-abf97b01187719b0a709334cbe0bad5724bf09c2422951891476cb275fa23b423</citedby><cites>FETCH-LOGICAL-c394t-abf97b01187719b0a709334cbe0bad5724bf09c2422951891476cb275fa23b423</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S014521260400387X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15755512$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kropff, Martin H.</creatorcontrib><creatorcontrib>Bisping, Guido</creatorcontrib><creatorcontrib>Wenning, Doris</creatorcontrib><creatorcontrib>Volpert, Sarah</creatorcontrib><creatorcontrib>Tchinda, Joëlle</creatorcontrib><creatorcontrib>Berdel, Wolfgang E.</creatorcontrib><creatorcontrib>Kienast, Joachim</creatorcontrib><title>Bortezomib in combination with dexamethasone for relapsed multiple myeloma</title><title>Leukemia research</title><addtitle>Leuk Res</addtitle><description>Fifteen patients with advanced multiple myeloma were scheduled to receive bortezomib 1.3
mg/m
2 IV days 1, 4, 8, and 11 every 3 weeks for eight cycles in combination with dexamethasone. One patient (7%) achieved a complete response, 10 (67%) a partial response, and one (7%) a minor response (MR) resulting in an overall response rate (≥MR) of 80% (9/9 with ≥ 2nd untreated and 3/6 with refractory relapse). Responses occurred after a median of 3 weeks and were independent of conventional prognostic parameters including deletion of chromosome 13. Adverse events, mainly myelosuppression, neuropathy and fatigue, were manageable.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Boronic Acids - administration & dosage</subject><subject>Bortezomib</subject><subject>Chromosomes, Human, Pair 13 - genetics</subject><subject>Dexamethasone</subject><subject>Dexamethasone - administration & dosage</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Prognosis</subject><subject>Pyrazines - administration & dosage</subject><subject>Remission Induction</subject><subject>Salvage Therapy</subject><subject>Sequence Deletion</subject><subject>Treatment Outcome</subject><issn>0145-2126</issn><issn>1873-5835</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtP3DAUhS0EginlJxRlxS6prx_jeFUV1KeQ2MDasp0b4WkcD3ZSSn89Gc1ILFmdzXfuufoI-QS0AQrrz5tmwPlPxtIwSkUD0CxxRFbQKl7LlstjsqIgZM2Arc_Ih1I2lFKpQZ-SM5BKSglsRX5fpzzh_xSDq8JY-RRdGO0U0lg9h-mx6vCfjTg92pJGrPqUq4yD3RbsqjgPU9gOWMUXHFK0H8lJb4eCF4c8Jw_fv93f_Kxv7378uvl6W3uuxVRb12vlKCyPKtCOWkU158I7pM52UjHheqo9E4xpCa0GodbeMSV7y7gTjJ-Tq_3dbU5PM5bJxFA8DoMdMc3FrJWk0PL2XRC0YC0HvYByD_qcSsnYm20O0eYXA9TsbJuNOdg2O9sGwCyx9C4PA7OL2L21DnoX4MsewMXH34DZFB9w9NiFjH4yXQrvTLwCxp6TUg</recordid><startdate>20050501</startdate><enddate>20050501</enddate><creator>Kropff, Martin H.</creator><creator>Bisping, Guido</creator><creator>Wenning, Doris</creator><creator>Volpert, Sarah</creator><creator>Tchinda, Joëlle</creator><creator>Berdel, Wolfgang E.</creator><creator>Kienast, Joachim</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20050501</creationdate><title>Bortezomib in combination with dexamethasone for relapsed multiple myeloma</title><author>Kropff, Martin H. ; Bisping, Guido ; Wenning, Doris ; Volpert, Sarah ; Tchinda, Joëlle ; Berdel, Wolfgang E. ; Kienast, Joachim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c394t-abf97b01187719b0a709334cbe0bad5724bf09c2422951891476cb275fa23b423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Boronic Acids - administration & dosage</topic><topic>Bortezomib</topic><topic>Chromosomes, Human, Pair 13 - genetics</topic><topic>Dexamethasone</topic><topic>Dexamethasone - administration & dosage</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Prognosis</topic><topic>Pyrazines - administration & dosage</topic><topic>Remission Induction</topic><topic>Salvage Therapy</topic><topic>Sequence Deletion</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kropff, Martin H.</creatorcontrib><creatorcontrib>Bisping, Guido</creatorcontrib><creatorcontrib>Wenning, Doris</creatorcontrib><creatorcontrib>Volpert, Sarah</creatorcontrib><creatorcontrib>Tchinda, Joëlle</creatorcontrib><creatorcontrib>Berdel, Wolfgang E.</creatorcontrib><creatorcontrib>Kienast, Joachim</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Leukemia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kropff, Martin H.</au><au>Bisping, Guido</au><au>Wenning, Doris</au><au>Volpert, Sarah</au><au>Tchinda, Joëlle</au><au>Berdel, Wolfgang E.</au><au>Kienast, Joachim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bortezomib in combination with dexamethasone for relapsed multiple myeloma</atitle><jtitle>Leukemia research</jtitle><addtitle>Leuk Res</addtitle><date>2005-05-01</date><risdate>2005</risdate><volume>29</volume><issue>5</issue><spage>587</spage><epage>590</epage><pages>587-590</pages><issn>0145-2126</issn><eissn>1873-5835</eissn><abstract>Fifteen patients with advanced multiple myeloma were scheduled to receive bortezomib 1.3
mg/m
2 IV days 1, 4, 8, and 11 every 3 weeks for eight cycles in combination with dexamethasone. One patient (7%) achieved a complete response, 10 (67%) a partial response, and one (7%) a minor response (MR) resulting in an overall response rate (≥MR) of 80% (9/9 with ≥ 2nd untreated and 3/6 with refractory relapse). Responses occurred after a median of 3 weeks and were independent of conventional prognostic parameters including deletion of chromosome 13. Adverse events, mainly myelosuppression, neuropathy and fatigue, were manageable.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>15755512</pmid><doi>10.1016/j.leukres.2004.11.004</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0145-2126 |
| ispartof | Leukemia research, 2005-05, Vol.29 (5), p.587-590 |
| issn | 0145-2126 1873-5835 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67501838 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adolescent Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Boronic Acids - administration & dosage Bortezomib Chromosomes, Human, Pair 13 - genetics Dexamethasone Dexamethasone - administration & dosage Female Humans Male Middle Aged Multiple myeloma Multiple Myeloma - drug therapy Neoplasm Recurrence, Local - drug therapy Prognosis Pyrazines - administration & dosage Remission Induction Salvage Therapy Sequence Deletion Treatment Outcome |
| title | Bortezomib in combination with dexamethasone for relapsed multiple myeloma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T17%3A43%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bortezomib%20in%20combination%20with%20dexamethasone%20for%20relapsed%20multiple%20myeloma&rft.jtitle=Leukemia%20research&rft.au=Kropff,%20Martin%20H.&rft.date=2005-05-01&rft.volume=29&rft.issue=5&rft.spage=587&rft.epage=590&rft.pages=587-590&rft.issn=0145-2126&rft.eissn=1873-5835&rft_id=info:doi/10.1016/j.leukres.2004.11.004&rft_dat=%3Cproquest_cross%3E67501838%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19428319&rft_id=info:pmid/15755512&rft_els_id=S014521260400387X&rfr_iscdi=true |